Zifi CV 50 Dry Syrup is a combination antibiotic formulation containing Cefixime 50 mg and Clavulanic Acid 31.25 mg per dose, designed for pediatric use. Cefixime, a third-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, effective against a wide range of Gram-positive and Gram-negative pathogens. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Cefixime by preventing enzymatic degradation of the antibiotic, thereby extending its spectrum against beta-lactamase producing resistant bacteria. This synergistic combination is indicated for the treatment of various bacterial infections including respiratory tract infections, otitis media, urinary tract infections, skin and soft tissue infections, and other susceptible infections in children. Zifi CV 50 Dry Syrup is administered orally after reconstitution with water, providing a palatable formulation suitable for pediatric patients. Dosage and duration of therapy should be determined based on the severity of infection and patient-specific factors, under medical supervision. Caution is advised in patients with hypersensitivity to cephalosporins or penicillins. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort. Proper adherence to prescribed dosage and completion of the full course is essential to prevent resistance development.